Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed CD20+ follicular lymphoma grade 1, 2 or 3a~* Have no prior systemic treatment for lymphoma.~* Must be in need of treatment~* Bi-dimensionally measurable disease with at least one mass lesion \> 2 cm that was not previously irradiated.~* Stage II, III or IV disease.~* Must be ≥ 18 years and sign an informed consent.~* Performance status ≤ 2 on the ECOG scale.~* Adequate hematological function (unless abnormalities are related to lymphoma infiltration of the bone marrow)~* Willing to follow pregnancy precautions~Exclusion Criteria:~* Clinical evidence of transformed lymphoma by investigator assessment or Grade 3b follicular lymphoma.~* Patients taking corticosteroids during the last 4 weeks, unless administered at a dose equivalent to \< 10 mg/day prednisone (over these 4 weeks).~* Major surgery (excluding lymph node biopsy) within 28 days prior to signing informed consent.~* Known Seropositive for or active viral infection with hepatitis B virus (HBV), hepatitis C virus (HCV)or human immunodeficiency virus (HIV).~* Life expectancy \< 6 months.~* Known sensitivity or allergy to murine products.~* Prior history of malignancies, other than follicular lymphoma, unless the patient has been free of the disease for ≥ 10 years.~* Prior use of lenalidomide.~* Neuropathy \> Grade 1.~* Presence or history of CNS involvement by lymphoma.~* Patients who are at a high risk for a thromboembolic event and are not willing to take venous thromboembolic (VTE) prophylaxis.~* serum aspartate transaminase (AST/SGOT) or alanine transaminase (ALT/SGPT) \> 3x upper limit of normal (ULN), except in patients with documented liver or pancreatic involvement by lymphoma~* total bilirubin \> 2.0 mg/dl (34 µmol/L) except in cases of Gilberts Syndrome and documented liver involvement by lymphoma~* creatinine clearance of \< 30 mL/min~* Pregnant or lactating females.~* Any condition, including the presence of laboratory abnormalities, which places the patient at unacceptable risk if he/she were to participate in the study, or which confounds the ability to interpret data from the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lenalidomide + Rituximab (Type: EXPERIMENTAL): * Lenalidomide dose 20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3\~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles~* Rituximab, 375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
- Control (Type: ACTIVE_COMPARATOR): • ONE of the following: Rituximab - CHOP, Rituximab - CVP, Rituximab - Bendamustine. 7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).